3/26/2020 8:05:33 AM
Lipocine Reports Outcome Of Markman Hearing In Patent Infringement Suit Against Clarus
2/25/2020 8:33:19 AM
Lipocine Announces $6 Mln Registered Direct Offering Priced At-The-Market
2/24/2020 7:08:38 AM
Lipocine Announces Results Of Post Action Meeting For TLANDO NDA; Says Regulatory Path Forward For TLANDO Resubmission
11/11/2019 6:31:32 AM
Lipocine Receives Complete Response Letter For TLANDO From FDA
8/7/2019 8:08:40 AM
Lipocine Q2 Net Loss $3.4 Mln Or $0.14/shr Vs. Net Loss Of $3.3 Mln Or $0.15/shr Prior Year
7/23/2019 8:04:23 AM
Lipocine Gets FDA Clearance For Clinical Testing Its NASH Candidate, LPCN 1144, In Expanded Target Population
5/8/2019 8:04:41 AM
Lipocine Q1 Net Loss $3.2 Mln Or $0.14/shr Vs Net Loss Of $2.7 Mln Or $0.13/shr Prior Year
3/14/2019 8:07:50 AM
Lipocine Announces Presentation Highlighting Therapeutic Potential Of LPCN 1144 In NAFLD And NASH Selected For ENDO 2019
3/12/2019 8:06:39 AM
Lipocine Announces Top-line Results From 16-week Liver Fat Imaging Study With LPCN 1144
1/24/2019 8:08:42 AM
Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects